Evidence map›Paper›PMID 41940308›Full record

ArticleFrontiers in neurology

Clinician and patient perspectives on meaningful Parkinson's disease impacts for digital assessment.

Andrew Pearlmutter, Robert Ellis, M Judith Peterschmitt

Abstract read
In one paragraph

Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Andrew Pearlmutter *Research and Development, Sanofi, Cambridge, MA, United States.
Robert Ellis *Koneksa Health, New York, NY, United States.
M Judith Peterschmitt *Research and Development, Sanofi, Cambridge, MA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Novel clinical outcome measures that accurately track Parkinson's disease (PD) progression are required to enhance patient care by improving physician decision-making and optimizing clinical trial design. The Parkinson's Disease Functional Impacts Digital Instrument (PD-FIDI) is a smartphone-app and wrist-worn wearable-based digital endpoint instrument designed to remotely measure PD functional impacts, including severity, progression, and functional changes. Objectives: Evaluate clinician- and patient-perspectives on the most relevant and meaningful aspects of PD to incorporate into the PD-FIDI. Methods: An advisory panel of eight clinical experts guided a literature review of qualitative studies reporting patient perspectives on the everyday impacts of PD. Clinician perspectives were acquired from the same expert panel. The perspectives of people with PD were gathered through an online survey ( Results: Clinicians and patients considered a subset of motor (tremor, rigidity/stiffness, bradykinesia, global motor function, and hand and mobility difficulties) and non-motor (depression and fatigue) PD aspects to be most bothersome and meaningful if improved. Conclusions: PD aspects identified as highly meaningful were incorporated into the PD-FIDI's design where technically viable, operationally feasible, and safe. Results support the evaluation of the PD-FIDI in an ongoing clinical study which will determine the instruments' analytical and clinical validity and usability.

Indexed as

clinician and patient perspectivedigital endpoint instrumentParkinson's diseaseParkinson's disease functional impacts digital instrument (PD-FIDI)smartphone appwearable

Identifiers

PMID41940308
PMCPMC13048067

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.